Readers Edition. This is the (nearly) annual tradition of you, RPS readers, telling us where we went wrong in our annual ...

Kitty is one of the many terminal emulators for Linux and macOS. You probably don’t think much about your terminal emulator: it gets out of the way, letting you type on the command line and work with ...

Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...

Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...

News of an apparently impending sale to a strategic investor sent shares of Exact Sciences (NASDAQ: EXAS) skyward on Wednesday. The cancer diagnostics specialist's shares closed the day nearly 24% ...

Abbott sells a range of diagnostic products, including at-home Covid-19 tests. (Bing Guan/Bloomberg) Shares of the cancer diagnostics company Exact Sciences surged 25% late Wednesday, after a report ...

Tue 18 Nov 3.11pm • A team in the Breamish Valley, in Northumberland, used ancient maps and modern technology to pull off one of the country's biggest river restoration projects.

Scientists from the European Space Agency have significantly narrowed down the trajectory of the interstellar visitor 3I/ATLAS thanks to data from the alien comet's recent flyby of Mars, allowing for ...

Bloomer announced, "We are raising total full year revenue to between $3.22 billion and $3.235 billion, an increase of $78 million at midpoint. This includes screening revenue between $2.51 billion ...

Exact Sciences earns a BUY rating, driven by innovation in non-invasive cancer detection and the recent launch of Cancerguard. EXAS's core products—Cologuard, Oncotype DX, and OncoDetect—deliver ...

Exact Sciences has launched its long-awaited blood test designed to detect the early stages of multiple tumors, with a plan to sell it to consumers through a telehealth program in a bid to increase ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Exact Sciences announced on Wednesday that it acquired the rights to a blood-based ...